Home > Investors relations> News & events > Press releases Press releases Risk Disclosure These press releases are provided for your convenience only and are not necessarily updated. They may contain forward-looking information which is subject to risks and uncertainties that could cause the actual results to differ materially. Factors that may affect future operations and business of the company are described in the prospectus relating to the company’s public offering or in the company’s annual report. 2010 2009 2008 2007 2006 2005 2004-1998 December, 18  Cerep focuses on the development of profitable service activities December, 11  Oncology program / Confirmation of the clinical effects observed with CER227185 - Major achievements in the development of CER233790 and new tumour reversion promoters November 9  Third quarter 2006 consolidated results - Results improve in the second half of the year September, 29  Fisrt half-year consolidated 2006 results August, 29  Cerep wholly owned subsidiary, Hesperion, acquires Touchstone Research Inc. August, 11  Half year 2006 consolidated sales revenues August, 7  Cerep and Servier enter collaboration agreements for drug discovery and lead optimization May, 11  First quarter 2006 consolidated sales revenues May, 11  Cerep grants BioPrint® access to AstraZeneca May, 10  First quarter 2006 consolidated sales revenues March, 23  2005 Consolidated results February, 9  2005 consolidated sales revenues Company profile Cerep worldwide Cerep mission & strategy Key management & Board Analyst coverage Financials Highlights Prospects Key financials Stock News & events Press releases Conferences Shareholders' info Financial calendar Document publicly available Other Financial reports Investor contact Français :: Home :: Site map :: Legal notice :: Credits ::